Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab ; volume:14 ; number:6 ; day:16 ; month:10 ; year:2019 ; pages:647-656 ; date:12.2019
Targeted oncology ; 14, Heft 6 (16.10.2019), 647-656, 12.2019
- Urheber
-
Kolberg, Hans-Christian
Colleoni, Marco
Santi, Patricia
Demetriou, Georgia Savva
Segui-Palmer, Miguel Angel
Fujiwara, Yasuhiro
Hurvitz, Sara A.
Hanes, Vladimir
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-019-00675-z
- URN
-
urn:nbn:de:101:1-2020032017520485515339
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kolberg, Hans-Christian
- Colleoni, Marco
- Santi, Patricia
- Demetriou, Georgia Savva
- Segui-Palmer, Miguel Angel
- Fujiwara, Yasuhiro
- Hurvitz, Sara A.
- Hanes, Vladimir
- SpringerLink (Online service)
Ähnliche Objekte (12)
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties